[NH2:1][C:2]1[S:6][N:5]=[C:4]([S:7][CH2:8][C:9]2[C:19]3[CH2:18][CH2:17][N:16](C(OC(C)(C)C)=O)[CH2:15][CH2:14][C:13]=3[CH:12]=[CH:11][C:10]=2[Cl:27])[N:3]=1.FC(F)(F)C(O)=O>C(Cl)Cl>[NH2:1][C:2]1[S:6][N:5]=[C:4]([S:7][CH2:8][C:9]2[C:19]3[CH2:18][CH2:17][NH:16][CH2:15][CH2:14][C:13]=3[CH:12]=[CH:11][C:10]=2[Cl:27])[N:3]=1To a solution of 6-(5-amino-[1,2,4]thiadiazol-3-ylthiomethyl)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.186 g, 0.436 mmol) in anhydrous DCM (10 mL) at room temperature add trifluoroacetic acid (10 mL) and stir the solution at room temperature overnight. Concentrate in vacuo and elute the residue through a SCX column (20 g). Dissolve the residue in DCM/methanol, add silica gel (5 g) and concentrate to a powder. Load the powder on to a dry column attached to a RediSep® column (40 g) and purify the crude mixture by preparative liquid chromatography (100:0 to 80:20 DCM/2M ammonia in methanol over 33 min; 80:20 DCM/2M ammonia in methanol over 33 min; 35 mL/min) to afford 6-(5-amino-[1,2,4]thiadiazol-3-ylthiomethyl)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.102 g, 72%). MS (ES+) m/z: 327.1 (M+H)+.
Loading…
